Top Gum in the First Quarter: Record Revenue Meets a Cash Conversion Lag
Top Gum opened 2026 with record revenue of $31.9 million and adjusted EBITDA of $5.3 million, but operating cash flow remained negative. After $35 million of Island Abbey payments and the US pharma acquisition, the next proof point is whether North American growth can turn into cash.
Top Gum opened 2026 with a quarter that proves gummy supplement demand has moved from narrative to numbers: $31.9 million of revenue, 81% of it from nutritional supplements, and a backlog of about $52 million for delivery over the coming quarters. But a reader who stops at record revenue and $5.3 million of adjusted EBITDA misses the active constraint: operating cash flow is still negative, working capital is still absorbing cash, and Island Abbey payments took $35 million out of the company during the quarter. The cash balance did not collapse because the company rebuilt part of it through warrant exercise proceeds, bank credit, and loans, which is why March ended with $26.7 million of cash and no immediate liquidity stress. Still, that is not the same flexibility the company would show if the business itself were funding the growth. The US acquisition after the balance-sheet date adds a facility, employees, and a shorter supply chain, but also $10 million of cash consideration, shares, contingent shares, and a long facility lease. The next few quarters need to show that the North American platform produces not only sales velocity, but also stronger reported gross margin, collections, and cash flow.
Company Orientation
Top Gum no longer looks like a local confectionery company with a supplement activity attached to it. The core economic engine is now the development and manufacturing of gummy supplements for other brands, a CDMO activity, meaning contract development and manufacturing for customers that sell the final product to consumers. The confectionery segment still exists, mostly in Israel, but in the first quarter it became a secondary layer: $6.1 million of revenue versus $25.8 million in nutritional supplements.
The company trades at a market capitalization of about NIS 1.86 billion, so the market is judging whether the North American growth rate can support a more expensive operating platform, with a new plant in Israel, Canadian operations, and the US activity acquired after the balance-sheet date. That is the context following the prior analysis of the US pharma acquisition: closing the transaction is no longer the main point. The question now is whether these layers become recurring revenue and cash without working capital absorbing the growth.
Growth Is Real, Reported Margin Is Not Clean Yet
The strong number this quarter is not only the revenue increase, but where it came from. Revenue reached $31.9 million, up about 85% year over year, but almost all of the change came from nutritional supplements. That segment grew to $25.8 million, up about 162%, and reached 81% of group sales. Confectionery and other revenue fell to $6.1 million, mainly because of weakness in the local market, competition, and Operation Roaring Lion, which hit a seasonal peak period.
The internal mix inside supplements says something else about growth quality. Sugar-based supplement sales jumped to $20.1 million, almost 3.8 times the comparable quarter, mainly thanks to Tailor Made products and the Canadian activity, where most products are sugar-based. Sugar-free supplement sales grew more moderately to $5.7 million. In other words, the main acceleration came from the place where Island Abbey and North American demand are now inside the numbers.
But reported margin does not yet give full confirmation of growth quality. Gross profit rose to $9.1 million, but gross margin declined to about 28.6%, compared with about 33.1% in the comparable quarter. In the supplement segment itself, gross margin fell from about 36.4% to about 30.1%. Management gives an important explanation: excluding tariffs, depreciation expenses tied to the new plant, and dollar weakness, gross margin would have been 34%. That is an adjusted comparison base, not the reported margin, so it mainly says the current problem is not necessarily demand. It is the cost of the transition.
The same gap appears further down the income statement. Adjusted EBITDA rose to $5.3 million and its margin rose to 17%, but operating profit was $1.26 million, slightly below the comparable quarter. Net profit jumped to $3.36 million mainly because of net finance income from dollar hedging and exchange-rate effects. That does not invalidate the quarter, but it does require caution around the net profit line: the true operating improvement still has to come through higher reported gross margin and lower transition costs.
Profit Did Not Reach Cash, and the Balance Was Preserved Through Capital and Debt
This is the most important gap in the report. Operating cash flow was negative $1.0 million, almost identical to the comparable quarter, despite net profit. The reason is not one dramatic item but growth that needs funding: receivables rose by $3.3 million, inventory rose by $0.9 million, and other payables fell by $4.2 million. Suppliers provided $3.0 million of support, but that was not enough to turn the business into a cash source during the quarter.
On an all-in cash flexibility basis, meaning after operating cash flow, investments, leases, interest, acquisition payments, debt, and equity proceeds, the quarter looks weaker than the headline but not weak. The company began the year with $31.4 million of cash and ended March with $26.7 million. During the quarter it paid $30 million of contingent consideration and $5 million of deferred consideration for Island Abbey, had $4.5 million of net investment outflow, and reported negative operating cash flow. What held the cash balance was $17.8 million of warrant exercise proceeds, net bank debt and credit, and a positive FX effect.
This breakdown matters because it separates two different claims. One claim is that the company does not face immediate liquidity stress. That is reasonable: equity rose to $114.9 million, the Island Abbey contingent and deferred consideration liability fell to zero after the payments, and the company still holds meaningful cash. The second claim is that the business already funds its own growth. That has not yet been proven. In the first quarter, the cash balance was preserved mainly by equity and debt, not by cash generated from operations.
The event missing from the March balance sheet is also the one investors should not ignore. After the balance-sheet date, the company paid $10 million in cash for the US activity acquired from PLD. Without assuming any other change, that payment alone brings the March cash balance down to about $16.7 million. That is still not an immediate pressure point, but it changes the room for maneuver against investments, working capital, and the integration still ahead.
The Pharma Deal Adds Capability, but Also Another Proof Point
The US acquisition is not just another strategic transaction. It changes the quality of the platform. The acquired activity includes a US pharmaceutical manufacturing facility, about 20 employees, active production lines, a laboratory line, products that have already been commercialized, and a development pipeline. The company will lease the production facility for 18 years at an annual cost of about $1 million. Consideration includes $10 million in cash, 1.89 million shares at closing, and up to 4.02 million additional shares subject to agreed commercial and regulatory targets.
The positive side is clear: a physical US presence can shorten the supply chain, bring the company closer to customers, and reduce some of the pressure created by tariffs on products manufactured in Israel and sold into the US. The tariff impact during the quarter was about $440 thousand. Products made in Canada are currently not directly tariffed under USMCA, but the agreement is expected to enter review in July 2026, and Israeli products still face a 10% tariff unless that changes. So the value of US manufacturing needs to appear in the numbers, not only in the geographic footprint.
The backlog gives the company a good starting point: about $52 million in nutritional supplements for delivery over the coming quarters, compared with about $36 million at the comparable date last year. The company is also focusing sales efforts on D2C customers, young brands that sell directly to consumers and rely on CDMO suppliers, which can shorten the development and sales cycle. That can support faster growth, but it also shifts the question: do these orders turn into revenue, are they collected, and does reported margin improve after the new Sderot plant stabilizes?
The new plant is part of the same equation. It began commercial activity in the fourth quarter of 2025, but product transfer is complex and includes new bills of materials, stability testing, line pilots, quality checks, and customer approvals. The process is expected to continue at least through the end of the second quarter of 2026, and in the meantime the company carries inefficiency costs from operating two plants in parallel. That explains part of the gross margin pressure, but it also creates a clear checkpoint: if reported margin does not move closer to management's adjusted level after the transition is completed, the market may conclude the issue is not only temporary.
Conclusion
The first quarter strengthens Top Gum's business story, but it does not close the cash story. Demand for gummy supplements in North America is now visible in the financial statements, backlog is high, and the Canadian activity changes the company's scale. Against that, reported gross margin declined, net profit benefited from currency hedges, and operating cash flow remained negative. The read is positive but incomplete: the company has proven sales velocity, and still needs to prove that velocity can produce cash after working capital, the new plant, tariffs, and acquisitions.
The strongest counter-thesis is that the market may be too patient with transition costs. If reported margin does not recover after the end of the second quarter, if backlog does not translate into collections, or if the US activity adds costs before it adds recurring orders, record revenue will look more like an expensive growth phase than an improvement in business quality. The read would improve over the next few quarters if three things arrive together: positive operating cash flow, stronger reported gross margin, and better disclosure around actual sales from the US platform. Until then, the stock remains particularly sensitive to small signs on cash, margins, and regulatory or commercial progress in the US.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.